Quick Answer
ENDRA Life Sciences Inc. reported Total Assets of $3.85 million for the year ending 2025.
- ENDRA Life Sciences Inc. showed a decrease of -13.4% in Total Assets from 2024 to 2025.
- This data is from ENDRA Life Sciences Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $545.1 thousand | Q2 2017: $7.94 million | Q3 2017: $7.48 million | Q1 2018: $3.69 million | Q2 2018: $3.05 million | Q3 2018: $1.29 million | Q1 2019: $4.64 million | Q2 2019: $3.19 million | Q3 2019: $3.62 million | Q1 2020: $4.40 million | Q2 2020: $2.86 million | Q3 2020: $5.36 million | Q4 2020: $8.76 million | Q1 2021: $18.90 million | Q2 2021: $17.24 million | Q3 2021: $15.31 million | Q1 2022: $10.94 million | Q2 2022: $15.31 million | Q3 2022: $12.34 million | Q1 2023: $6.65 million | Q2 2023: $9.24 million | Q3 2023: $7.60 million | Q1 2024: $5.06 million | Q2 2024: $10.44 million | Q1 2025: $3.17 million | Q2 2025: $2.81 million | Q3 2025: $1.96 million.
- Over the full 10 years of available data (2016 to 2025), ENDRA Life Sciences Inc.'s Total Assets has grown by 685.3%.
- Historical annual values: Fiscal year 2025: $3.85 million | Fiscal year 2024: $4.45 million | Fiscal year 2023: $6.75 million | Fiscal year 2022: $9.27 million | Fiscal year 2021: $12.87 million | Fiscal year 2020: $8.76 million | Fiscal year 2019: $7.18 million | Fiscal year 2018: $7.22 million | Fiscal year 2017: $6.12 million | Fiscal year 2016: $490.8 thousand.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: